Objective: Pregnancy-associated plasma protein-A (PAPP-A) has been implicated in the atherosclerotic process through regulation of local expression of IGF1. In type 2 diabetes mellitus, glycaemic control has been involved in PAPP-A expression. We compared PAPP-A, IGF1, inflammatory markers and adiponectin concentrations in type 2 diabetic patients with and without carotid plaques and evaluated the relationship between these serum parameters and ultrasound carotid markers of atherosclerosis. Methods: We studied 125 consecutive type 2 diabetic patients. Clinical data, metabolic variables, hemostatic factors (plasma type-1 plasminogen activator inhibitor, fibrinogen), high-ultrasensitive C reactive protein (hsCRP), tumor necrosis factor (TNF)-a, interleukin (IL)-6, adiponectin, IGF1 and PAPP-A were determined. Patients were classified into two groups according to the presence of carotid plaques on ultrasound. Carotid intima-media thickness (IMT) and morphology of carotid plaques were evaluated. Results: The mean age was 61.5G7.3 years and the mean glycated hemoglobin of 6.8G0.9%. A total of 60% presented carotid plaques. Both groups were homogeneous in anthropometric data, biochemical determinations and hemostatic factors. Adiponectin, hsCRP, TNF-a and IL-6 were similar in both groups. No differences were observed in serum PAPP-A (0.46 (0.22-0.86) vs 0.38 (0.18-0.66) mIU/l and in SDS IGF1 (K0.34G1.38 vs K0.67G1.35)) in patients with and without carotid plaques respectively. PAPP-A and IGF1 were not correlated with IMT. Conclusions: Serum PAPP-A and IGF1 do not appear to be useful serum biomarkers for carotid atherosclerosis in type 2 diabetic patients with stable glycemic control, despite scientific evidence of their local role in atherosclerosis.
Introduction
Cardiovascular disease is the leading cause of disability and premature mortality in patients with diabetes mellitus (DM) (1) . A strategy to efficiently reduce coronary morbidity and mortality in the diabetic population implies the capability of identifying patients in the early stage of atherosclerosis. Carotid ultrasound is a well-validated tool for studying the presence and progression of cardiovascular disease and allows accurate visualization of the morphology of vascular structures and the presence and characteristics of atherosclerotic plaques (2) . Common carotid artery (CCA) intima-media thickness (IMT) and the presence of carotid plaques has already been used in epidemiologic and intervention studies as markers of subclinical arteriosclerosis (3) (4) (5) . On the other hand, previous carotid ultrasound studies have associated plaques with low echogenicity with a higher risk of cerebrovascular events (6, 7) .
Pregnancy-associated plasma protein-A (PAPP-A) is a zinc-binding matrix metalloproteinase which specifically degrades insulin-like growth factor (IGF) binding protein-4, thereby increasing levels of local bioactive unbound IGF1 in response to injury and could be involved in the pathogenesis of atherosclerosis (8) (9) (10) (11) (12) (13) . In recent years, it has been reported that PAPP-A is abundantly expressed in unstable coronary plaques (9) and elevated serum concentrations predict an adverse prognosis in acute coronary syndrome (14) (15) (16) .
However, recent evidence shows that local IGF1 may act to stabilize atherosclerosis plaques (17) and therefore, PAPP-A, through increasing bioavailable IGF1, may reflect a local response on stabilizing atherosclerotic plaques (12, 17) . There are few data about the relationship of serum PAPP-A concentrations and the presence and the stability of carotid atherosclerotic plaques. In fact, some studies (18, 19) have suggested that elevated serum PAPP-A concentrations may be a marker of the degree of echogenicity of carotid atherosclerotic lesions.
Several large studies have reported that IGF1 deficiency may contribute to atherothrombotic diseases (20) (21) (22) . Moreover, placebo-controlled trials have shown that GH replacement in GH deficient patients improves carotid risk cardiovascular factors such as IMT (23) . In addition, serum IGF1 concentrations have recently been inversely associated with instability or echolucency of carotid plaques (24) . On the other hand, treatment with IGF1 significantly improved glycaemic control in type 2 diabetic subjects (25) . Recent data in a large number of patients have suggested that higher IGF1 bioavailability may improve metabolic control and prevent vascular complications in type 2 diabetic patients (20) . However, the association between PAPP-A concentrations and DM is less known. In a recent report, we found significantly lower serum PAPP-A concentrations in type 2 diabetic patients compared with age-and sex-matched controls without cardiovascular disease (26) . In this study, PAPP-A concentrations showed a significant inverse correlation with glycated hemoglobin (HbA1c), independently of other clinical and metabolic factors, suggesting that glycaemic control may influence the regulation of PAPP-A expression (26) .
To our knowledge, the relationship between PAPP-A and IGF1 and the presence and morphology of carotid plaques in type 2 DM have not been previously described. We aimed to test the hypothesis that a decrease in serum PAPP-A and IGF1 is associated with an increased IMT and with the presence and echolucency of carotid plaques in patients with type 2 DM with stable glycaemic control, to thereby determine whether these parameters might be useful markers of carotid atherosclerosis in type 2 diabetic patients.
Subjects and methods
Consecutive type 2 diabetic patients seen at two outpatient clinics from February 2006 to June 2006 were studied. The diagnosis of type 2 DM was made according to the 1997 criteria of the American Diabetes Association (27) . In order to achieve strict homogeneity of the subject samples, inclusion criteria considered for the study were: i) diabetic patients on therapy with diet or oral antidiabetic drugs at initial diagnosis and absence of antibodies to glutamic acid decarboxylase; ii) HbA1c!7.5% in the last 12 months on four determinations; iii) absence of diagnosis or symptoms of acute cardiovascular disease or peripheral vascular disease 6 months prior to inclusion and iv) absence of acute or chronic systemic inflammatory disease, pregnancy and history or presence of any malignancy.
Clinical macrovascular disease included any documented episode of myocardial infarction, angina, cerebrovascular disease or peripheral artery disease. Diabetic nephropathy was evaluated according to urinary albumin excretion. Thus, normal urinary albumin excretion was considered below 30 mg/24 h, microalbuminuria from 30 to 300 mg/24 h and proteinuria above 300 mg/dl. These results were confirmed on at least two out of three consecutive determinations. Diabetic retinopathy was defined by fundus oculi performed by a specialized ophthalmologist. Hypertension was defined as systolic blood pressure (BP) over 140 mmHg and/or diastolic BP over 90 mmHg or, alternatively, if patients were on antihypertensive therapy. Hypercholesterolemia was defined by total serum cholesterol exceeding 5.2 mmol/l or, alternatively, if patients were taking statins.
The study was approved by the local ethics committee, in accordance with the Declaration of Helsinki and all participants gave their written informed consent prior to inclusion.
Measurements
Demographic and clinical data, including age, sex and history of clinical macrovascular disease and microvascular diabetic complications were recorded in all subjects. Body mass index (BMI), systolic BP and diastolic BP were determined. BMI was calculated as weight in kilograms divided by height per square meter. Systolic BP and diastolic BP were measured by sphygmomanometer by the same physician as the mean of three determinations.
Biochemical measurements
Blood samples were drawn by venipuncture at between 0700 and 0800 h after an overnight fast. Plasma glucose, total cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides and uric acid were measured by routine clinical chemistry immediately after extraction. Non-HDL cholesterol was calculated as the difference between total cholesterol and HDL-cholesterol. HbA1c was measured in blood samples with EDTA by HPLC using a fully-automated Adams Menarini HI-AUTO A1c 8160 analyzer manufactured by Arkray (Kyoto, Japan) with an inter-assay coefficient of variation (CV) of 1.8 and 1.5% at HbA1c levels of 4.8 and 9.0% respectively (reference range: 4-5.8%). Serum samples for the remaining biochemical measurements were immediately frozen and stored at K80 8C until assayed and were analyzed together under the same analytical conditions. High-ultrasensitive C-reactive protein (hsCRP) was measured in serum by nephelometry using BN-ProSpecT (Dade Behring, GmbH, Marburg, Germany) with an inter-assay CV 3.7 and 3.5% for hsCRP concentrations of 2.38 and 52.2 mg/l respectively. Immunoreactive insulin levels were determined using an automated electrochemiluminiscence immunoassay (Modular E, Roche Diagnostics GmbH). The sensitivity of the process was 0.2 mUI/l. The inter-assay variation coefficients were 2.5, 2.8 and 2.1% for mean insulin values of 6.4, 20.9 and 88 mUI/l. Insulin resistance was determined using homeostasis model assessment of insulin resistance (HOMA-IR) and calculated using fasting glucose and insulin using the following formula: HOMA-RI-indexZfasting insulin (mUI/l)!fasting glucose (mmol/l)/22.5. Serum IGF1 concentrations were measured by a chemiluminescent enzyme immunometric assay (IMMULITE 2000, Diagnostic Products Corp., Los Angeles, CA, USA). Intra-assay CV was 6.3 and 4.9% and inter-assay CV was 7.5, 3.5 and 4.0% for IGF1 concentrations of 78.2, 247.3, and 552.8 mg/l respectively. Assay sensitivity was 25 mg/l. Ultrasensitive PAPP-A was measured in serum using an ELISA (DSL, Active US PAPP-A ELISA Diagnostic Systems Laboratories Inc., Webster, TX, USA), with an inter-assay CV of 8.5 and 5.3% for PAPP-A concentrations of 2.5 and 10 mU/l respectively. Serum tumor necrosis factor-a (TNF-a) and interleukin (IL-6) concentrations were measured using an enzyme chemiluminescence immunometric assay (Immulite One, Siemens, Los Angeles, CA, USA). The inter-assay CV for TNF-a was 2.5 and 4.8% for TNF-a concentrations of 96 and 567 pg/ml respectively. The inter-assay CV was 3.7 and 5.9% for IL-6 concentrations of 78 and 459 pg/ml respectively. Serum adiponectin concentrations were measured by a commercial double antibody RIA (Linco Research, Inc., St Louis, MO, USA). The intra-and inter-assay CV were below 6.2 and 9.2% respectively. Assay sensitivity was 1 mg/ml. All plasma samples were diluted 1:250, to yield an effective range of 0.2-50 mg/ml. Fibrinogen was measured by a coagulometric assay using thrombin (Clauss' method). Plasma type-1 plasminogen activator inhibitor (PAI-1) antigen was measured by an ELISA based on a double antibody principle (Trinity Biotech, St Louis, MO, USA).
Ankle/brachial index measurement
All measurements were taken in a room maintained at 23-25 8C after at least 30 min of acclimatization. Ankle/brachial index (ABI) was determined three times by the same observer as the ankle systolic BP-brachial systolic BP ratio. Doppler ankle pressure was measured in dorsal pedial arteries beginning with the right side on supine decubitus position. If dorsal pedial arteries could not be found, the posterior tibial arteries were used instead. Both brachial and ankle pressures were measured with a hand-held Doppler (Mini-Doppler, model ES-100X; Hadeco Inc., Kawasaki, Japan). ABI was calculated as the highest ankle systolic BP divided by the highest brachial systolic BP. The lower ABI value obtained (right or left side) was used for analysis. An ABI!0.9 was considered abnormal.
Carotid ultrasound
Ultrasonographic images were acquired using highresolution B-mode ultrasound (Acuson Sequoia C-256) with an electric linear transducer (Multifrequency 8L5). Acquisition, processing and storage of B-mode images were computer-assisted with the new version of the software provided by the manufacturer. All measurements were taken by the same trained ultrasonographer. The CCA segment was defined as the distal 1 cm of the CCA, immediately proximal to the onset of increased spatial separation of the walls of the CCA. Both near and far walls of these arterial segments were scanned longitudinally and transversely to assess the presence of plaques. The protocol involved scanning of the CCA, carotid bifurcations and origins (first 2 cm) of internal carotid arteries. The presence of carotid plaques was defined as focal echo structures encroaching into the arterial lumen of at least 0.5 mm or 50% of the surrounding IMT value, or when IMT was O1.5 mm as measured from the media-adventitia interface to the intima-lumen interface. Analysis of carotid plaques included location, number, thickness and grade of echogenicity. Quantification of plaque thickness was made at the site of the maximal encroachment perpendicularly to the vessel wall by measuring the distance between the media-adventitia interface and the lesion surface facing the lumen. In subjects with plaques, the total number of sites with plaques was calculated and ranged from 1 to 4 or more than four in all arterial segments.
Plaque morphology, in terms of ultrasound echogenicity, was graded as echogenic, echolucent and heterogeneous. The vessel lumen was used as the reference structure for defining echolucency, and the echo zone produced by the media-adventitia interface in the far wall as the reference for echogenicity. When several plaques were detected in the same arterial segment, only the echogenicity of that with the greatest encroachment into the lumen was recorded.
CCA-IMT was measured in a longitudinal view at a site free of plaques along a 10 mm-long segment on the far wall of the CCA in agreement with the carotid IMT consensus (2004) (2005) (2006) (2) . Composite right and left CCA-IMT were calculated as the average of the four readings in each artery segment, and the mean of the left and right CCA-IMT measurements was used in the analysis.
Diabetic patients were classified into two groups according to presence or absence of carotid plaques on ultrasound. 
Statistical methods

Results
One hundred and twenty-five diabetic patients (56.3% men) were included. The mean age was 61.5G7.3 years and the mean DM duration was 14.1G9.9 years. In the overall group, 27.9% were treated with insulin alone, 40.1% with oral antidiabetic drugs alone, and 32.1% with both therapies. Diabetic retinopathy was detected in 37.8% and diabetic nephropathy in 25.5% (15.6% microalbuminuria, 9.9% macroalbuminuria). The mean HbA1c was 6.8G0.9, hypercholesterolemia was detected in 34.6% (72.7% on statin therapy, 12.5% on fibrate therapy), 80.7% had hypertension and 67.9% of patients received treatment with aspirin.
Seventy-five (54 men) patients presented carotid plaques (29.3% previous coronary artery disease, 10.7% stroke, 2.7% amputation), and 50 patients (17 men) did not (20.4% previous coronary artery disease, 2.1% stroke). Fifty-six (74.6%) patients with carotid plaques were on statin therapy, 15 (20%) on fibrate therapy and 81.7% on antihypertensive treatment (angiotensin-converting enzyme inhibitor or angiotensin receptor type 2 antagonist). In the group without carotid plaques, 70% were in statin treatment, and 80% in antihypertensive therapy. Clinical and biochemical characteristics are shown in Table 1 . There were no differences in DM duration (14.8G9.7 vs 13.1 G10.0 years) between the two groups. Anthropometric data and glycaemic control were homogeneous. As expected, there were significantly more patients with ABI!0.9 among those with carotid plaques (PZ0.02). Total cholesterol and non-HDL cholesterol levels in diabetic patients without carotid plaques were not significantly higher than patients with carotid plaques. There were no differences between the two groups in plasma fibrinogen or PAI-1. TNF-a levels were significantly higher in patients with carotid plaques (PZ0.04), but hsCRP, IL-6 and adiponectin concentrations were similar in the two groups of patients (Table 1) .
No differences were observed in PAPP-A levels and SDS IGF1 between patients with and without carotid plaques (Table 1) and neither were there differences between PAPP-A levels and SDS IGF1 irrespective of smoking habit, the presence of microvascular (nephropathy and retinopathy) or macrovascular complications and cholesterol levels. No differences were found between patients with and without carotid plaques when they were analyzed with respect to therapy with statin, fibrate or antihypertensive drugs (data not shown). Table 2 shows the results of lineal regression analyses of the significant parameters studied. The hsCRP correlated positively with IL-6 (PZ0.001) and negatively with SDS IGF1 (P!0.01) in both groups of patients. CCA-IMT correlated positively with the inflammatory markers IL-6 (PZ0.01), hsCRP (PZ0.002) and TNF-a (PZ0.03) in patients with carotid plaques and negatively with microalbuminuria (PZ0.003) in patients without carotid plaques. There was not a correlation between the analytical and echographic parameters studied and PAPP-A or SDS IGF1 (Table 2 ).
In the multivariate regression analysis including all significant variables for determining independent factors of CCA-IMT in patients with and without carotid plaques, none of the variables included (PAPP-A, SDS IGF1, adiponectin, IL-6, TNF-a, hsCRP, HbA1c and lipids) were significant predictors (data not shown).
In the analyses of the subgroup of diabetic patients not treated with insulin, with (nZ22) and without (nZ20) carotid plaques, the insulin resistance and glycaemic variables (insulin, HOMA, HbA1c, glycaemia) were not correlated with the other parameters studied in the bivariate analyses and they were not significant predictors for CCA-IMT in the multivariate model (data not shown).
Discussion
To our knowledge, circulating concentrations of metalloproteinase PAPP-A and IGF1 have not been evaluated in relation to carotid atherosclerosis in type 2 diabetic patients with acceptable glycaemic control. In this study, no differences were found in serum PAPP-A concentrations and SDS IGF1 between diabetic patients with carotid plaques and those without carotid plaques with similar metabolic control. Neither was any relation observed between these two serum parameters and the echogenicity of carotid plaques in diabetic patients. Therefore, serum PAPP-A and IGF1 may not be useful as serum markers for carotid atherosclerosis in type 2 DM.
Our results differ from those of previous studies that proposed increased PAPP-A concentrations as a marker for early-stage atherosclerosis (19, 28) . However, an increase in serum PAPP-A could be the consequence of a repair mechanism associated with local modulation of IGF1 in the atherosclerotic process. In fact, PAPP-A cleaves IGF1 from its binding protein-4, thereby increasing the accessibility of free IGF1 to tissues. Although IGF1 has been considered to be a mediator of plaque growth in vitro (17) , emerging clinical and experimental evidence suggest that IGF1 acts as a promoter of repair in damaged tissues by its action on vasodilatation, vasculogenesis and insulin sensitivity on one hand and on the other hand by its ability to stimulate migration, proliferation and regeneration of endothelial and vascular smooth muscle cells (11, 12, 17) . Thus, in ischemic tissues there is a change in the regulatory system of IGF1, including a compensatory increase in PAPP-A aimed at expanding tissue IGF1 concentrations. Indeed, we previously described a negative relationship between PAPP-A concentrations and glycated hemoglobin in type 2 diabetic patients, in agreement with a hypothetical protective role of local PAPP-A/IGF1 in the atherosclerotic process. We found higher PAPP-A concentrations in those diabetic patients with a better metabolic control and cardiovascular profile, who were therefore susceptible to have an unaltered repair mechanism of atherosclerosis (26) . The lack of association observed in the present study between PAPP-A and parameters accepted as markers of atherosclerosis, such as the presence of carotid plaques, ABI and hsCRP may be explained, in part, by the complex role of PAPP-A in the repair response during the process of atherosclerosis. On the other hand, the significant correlations observed between the presence of carotid plaques and the CCA-IMT and atherosclerosis risk factors such as hsCRP and microalbuminuria are in agreement with previous literature in diabetic patients (29) .
Interestingly, we observed a negative correlation between SDS IGF1 and the atherosclerosis risk factor hsCRP in all diabetic patients in agreement with reports that showed that serum IGF1 concentrations in the lower rank might be considered as a cardiovascular risk factor (21) . PAPP-A was negatively correlated with microalbuminuria in patients without carotid plaques. This result is in agreement with our hypothesis that PAPP-A may reflect a protective and not an etiological mechanism of atherosclerosis, however, the small number of patients with microalbuminuria in the present study limits the statistical power of this observation. On the other hand, we have detected a correlation between inflammatory factors and the CCA-IMT in patients with carotid plaques highlighting the implication of inflammatory factors in the development of the atherosclerotic process. In our cohort of patients, we found IMT values rather thick. This finding is probably due to the fact that our cohort of diabetic patients had an extremely high risk atherosclerosis because of the long disease evolution. Table 2 Bivariate correlations (P value) for the significant parameters in diabetic patients with carotid plaques (CP) and without carotid plaques (No CP). No differences were observed in SDS IGF1 according to carotid plaques stability, although our result could be related to an insufficient number of patients with echolucent atherosclerotic plaques. Our results are different from those of Martin et al. who described a negative association between IGF1 and instability of carotid plaques when adjusted by IGFBP3 (24) . However, this study included older adults, apparently without diabetes and the authors indicated that caution was needed in interpreting positive results when these were present only after statistical adjustment. Measurement of circulating IGF1 as a serum biomarker of stability of atherosclerotic plaques should also be interpreted with caution because IGF1 is synthesized in the liver and may not reflect a local process such as rupture of atherosclerotic plaques. Previous conclusions about the relationship between PAPP-A concentrations and the carotid plaques morphology are controversial (6, 18, 19) .
We included only patients with stable metabolic control because in a previous study (26) , we observed that PAPP-A levels decreased as HbA1c increased and reached statistical significance at HbA1c levels of 8.2%, an accepted level of poor metabolic control. Our result of the lack of association of PAPP-A with IMT is in disagreement with a previous report (30) , although this may be explained by the inclusion of diabetic patients with a wide range of HbA1c in this study. On the other hand, in the present study, the lack of differences in lipids, fibrinogen and PAI-1 could be explained by the intense and extensive use of statins in diabetic patients according to present guidelines.
The absolute PAPP-A serum concentrations obtained in our study sample may, therefore, not be directly comparable with the PAPP-A concentrations reported by other authors (10, 15, 18, 31, 32) because of the different methods used for PAPP-A measurement. It is well known that atherosclerosis-related PAPP-A differs from pregnancy-related PAPP-A, since the first circulates as a homodimeric active form, uncomplexed with the proform of the eosinophil major basic protein (proMBP). Immunoassays used to detect total PAPP-A may not be accurate (32) . Thus, we used an ultrasensitive PAPP-A ELISA developed for measuring PAPP-A molecules but not the proMBP subunit to avoid false positive results.
In conclusion, our results suggest that the measurement of serum PAPP-A and IGF1 may not reflect the local activation of the PAPPA/IGF1 system as a repair mechanism in the atherosclerotic process. Thus, they do not appear to be useful as serological markers of the presence and severity of carotid plaques in well controlled type 2 DM. However, these findings are obtained from a cohort of type 2 diabetic patients with good glycemic control and therefore, should not be extrapolated to other type 2 diabetic patients with insufficient glycaemic control.
Although we understand that negative results are difficult to publish we feel that they are also important to avoid bias. Further investigations are required to clarify the role of PAPP-A and IGF1 in the atherosclerotic process in these patients.
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